Figure 1
From: Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
Comparing CMKLR1 antagonist α-NETA and FDA-approved Tecfidera (dimethyl fumarate, DMF) in suppressing experimental autoimmune encephalomyelitis (EAE). (A) Structure and features of α-NETA and DMF. (B) EAE was induced in C57BL/6 mice by active immunization with MOG35–55/CFA. Mice received α-NETA (10 mg/kg daily; n = 8 mice), DMF (10 mg/kg daily, n = 4 mice)), or vehicle control (10% captisol, n = 4 mice) beginning at the time of disease induction and were monitored daily for clinical disease as follows: 0, normal; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb and hind limb paralysis; 5, dead. Day of onset of clinical signs (assumes worst case scenario d29 onset for 2 mice in the α-NETA group). Mean + SEM, *p < 0.05, **p < 0.01 by one-way ANOVA. ns, not significant. (C) Mean clinical score - SEM. *p < 0.0001 by F-test (extra sum of squares) comparing the shapes of the 4th order polynomial curves for each treatment group, rejecting the null hypothesis that one curve fits all data sets. (D) The integrated clinical score over time for each animal was calculated as area under the curve (AUC). Mean + SEM, *p < 0.05, **p < 0.01 by one-way ANOVA.
